Cargando...

Potential use of STAT3 inhibitors in targeted prostate cancer therapy: future prospects

In 2012, prostate cancer will once again be the second-leading cause of cancer death of American males. Although initially treatable, prostate cancer can recur in a hormone refractory form that is not responsive to current available therapies. The mortality rate associated with hormone refractory pr...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Shodeinde, Adetola L, Barton, Beverly E
Formato: Artigo
Lenguaje:Inglês
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3400487/
https://ncbi.nlm.nih.gov/pubmed/22815644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S32559
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!